Author: miracellPH

Case of complete cure for psoriasis achieved through immunological approach

Psoriasis: Complete cure achieved with immunological approachProfessor Park Eun-soo of Soonchunhyang University announces results of Miracell stem cell treatment At the 2022 World Congress of Aesthetic Plastic Surgery (MCAS ASIA) held in Bangkok for three days from September 29th, stem cell company Miracell (CEO Shin Hyun-soon) and plastic surgeon Professor Eun-soo Park (Soonchunhyang University Bucheon Hospital) presented on the results of “stem cell treatment for refractory psoriasis.” Psoriasis is an intractable disease affecting approximately 2% of the global population. While steroid treatment is typically used, most patients experience relapses and remissions, leading to distress. Furthermore, there is ongoing debate within the academic community about whether psoriasis is a skin disease or an immunological disease. In this presentation, Professor Eun-soo Park presented a case of complete psoriasis cure after two intravenous injections of bone marrow stem cells and blood-derived cells from an immunological perspective. Professor Park Eun-soo stated, “The patient presented at this conference had been suffering from psoriasis for six years, and the severe, widespread psoriasis had prevented her from engaging in social activities. However, she was completely cured after autologous stem cell treatment. As psoriasis frequently relapses, we observed the patient’s progress after treatment, and only recently, after a year and six months, were we able to confidently share the results.” This treatment for the intractable skin disease psoriasis utilized Miracell’s advanced stem cell extraction system, Smart Mcell 2, along with the Bonemarrow kit and blood kit, which were used to selectively collect stem cells. Source: Doctors’ Newspaper (http://www.doctorsnews.co.kr)

International St. Mary’s Hospital and Miracell Sign Joint Stem Cell Research Agreement

International St. Mary’s Hospital and Miracell Sign Joint Stem Cell Research AgreementCooperation to Expand Clinical and Stem Cell Research and Development, and Invigorate the Medical and Biohealth Sectors Catholic Kwandong University International St. Mary’s Hospital (President Kim Hyun-soo) announced on the 27th that it had signed a business agreement with Miracell (CEO Shin Hyun-soon) for joint stem cell clinical research. The signing ceremony was attended by Father Kim Hyun-soo, President of International St. Mary’s Hospital; Professor Chae Dong-sik (Orthopedic Surgery), Director of the Cell Therapy Center; Miracell CEO Shin Hyun-soon, and representatives from both institutions. Under this agreement, International St. Mary’s Hospital will establish a cooperative relationship with Miracell to promote research and development to improve national health and advance future medical technologies. To this end, the two organizations agreed to closely collaborate on: ▲ joint clinical and stem cell research and development; ▲ research and development in future medical fields; and ▲ the revitalization of the medical and biohealth sectors. Father Kim Hyun-soo, Director of International St. Mary’s Hospital, said, “Contributing to the improvement of national health and welfare through cutting-edge medical care is a truly valuable endeavor.” “I hope this collaboration will provide an opportunity to provide more effective treatment to patients.” Meanwhile, Miracell is a stem cell company that conducts joint research and development with domestic and international medical institutions to specialize in safe stem cell treatments.

Miracell Presents Stem Cell Treatment Results for Intractable Skin Diseases at the World Congress of Aesthetic Plastic Surgery in Bangkok

Miracell presented its stem cell treatment for refractory skin conditions at the World Congress of Aesthetic Plastic Surgery in Bangkok. [Edaily Reporter Lee Soon-yong] Stem cell specialist Miracell (CEO Shin Hyun-soon) announced on the 5th that it presented the results of its “stem cell treatment for refractory skin” in collaboration with plastic surgeon Professor Park Eun-soo (Soonchunhyang University Bucheon Hospital) at the International Congress of Aesthetic Plastic Surgery (MCAS ASIA 2022), held in Bangkok, Thailand from September 29 to October 1. IMCAS ASIA is the Asian regional conference of IMCAS, one of the world’s top three aesthetic plastic surgery societies. It brings together plastic surgeons, dermatologists, and industry leaders from Asia and around the world to present and share the latest technologies and research in the field of medical aesthetics. Professor Eunsoo Park, who has conducted national projects on chronic wounds (such as diabetic foot and ischemic ulcers) and has conducted extensive research on regenerative treatments,attended this conference as a panelist and drew the attention of physicians worldwide with a presentation on “Cell Therapy and Regenerative Medicine, Advanced Cell and Tissue Therapy for Skin Aging and Lesions.” For the treatment of psoriasis, a refractory skin disease, stem cells selectively collected using the “Smart Mcell 2,” a cutting-edge stem cell extraction system developed by Miracell. This system regenerates damaged tissue by injecting total cells, including stem cells with a cell survival rate of up to 99%, growth factors, white blood cells, and platelets, into the wound. “Smart Mcell 2” is a cutting-edge biodevice that has received New Medical Technology Certification from the Ministry of Health and Welfare, been selected as a Public Innovation Product by the Public Procurement Service, and has been registered with the US FDA. It is recognized as an essential system in regenerative medicine. CEO Shin Hyun-soon stated, “There have been many cases of actual results from stem cell therapy for psoriasis, a rare and intractable immune disease with low treatment efficacy. At this international conference, I was able to present on the connection between immune diseases and the skin, and the results of cell therapy.” He continued, “Doctors from around the world have been asking questions about the specific stem cell treatments we used, including IV injections and topical skin treatments, and have raved about the excellent treatment results.” CEO Shin continued, “I am proud that this presentation has elevated Korea’s status in the advanced regenerative medicine bio market. We will continue to conduct clinical trials using our stem cell extraction system to treat more patients and achieve better outcomes.” Meanwhile, Miracell plans to attend “Medica 2022 in Germany,” a global medical industry gathering, on November 14th.

Miracell Expands Export Markets with Stem Cell System “Smart Mcell 2”

Miracell Expands Export Markets with Stem Cell System “Smart Mcell 2”Stem cell isolation within 17 minutes, with cell viability rates of up to 98% 【Health Digest | Reporter Choi Min-young】 Stem cell specialist Miracell (CEO Shin Hyun-soon) participated in the International Society of Aesthetic Plastic Surgery (ISAPS) World Congress, held in Istanbul, Turkey from September 20th to 24th, to showcase its stem cell extraction system, the “Smart Mcell 2.” According to the company, the “Smart Mcell 2” stem cell extraction system can be applied to a wide range of regenerative medicine procedures across the body. By incorporating stem cells into existing surgeries or performing them directly, the system enhances the regenerative capacity of cells, maximizing therapeutic effects. Stem cell treatments are also actively being used in the field of dermatological plastic surgery. Over 400 faculty members from over 70 countries participated in the 26th International Society of Aesthetic Plastic Surgery. CEO Shin Hyun-soon stated, “With growing interest in anti-aging, demand for stem cell systems has recently surged in the cosmetic surgery field.‘Smart Mcell 2’ boasts stem cell isolation within 17 minutes and a cell viability rate of up to 98%.” “We will work diligently to promote domestic stem cell technology, which plays a key role in increasing patient satisfaction in regenerative medicine, to the global biotechnology market.” Meanwhile, Miracell plans to attend the IMCAS International Congress of Aesthetic Plastic Surgery, to be held in Bangkok, Thailand, starting September 29th.

Recruiting Participants for Clinical Trial of Stem Cell Therapy for Cerebrovascular Disease in Patients with Vascular Dementia

Recruitment of participants for clinical trials of “cerebrovascular disease stem cell therapy” for patients with vascular dementia. 【Health Digest | Reporter Choi Min-young】 Cerebrovascular disease strikes unexpectedly. When a blood vessel supplying blood to the brain becomes blocked, a “cerebral infarction” occurs, and when it bursts, a “cerebral hemorrhage” occurs. Selpia Clinic, a stem cell regeneration clinic, announced on the 23rd that it is recruiting volunteers for a clinical trial to apply regenerative medicine stem cell therapy to treat vascular dementia, a cerebrovascular disease caused by brain tissue damage. The study targets patients under the age of 75 who have experienced recovery difficulties due to cerebral infarction or cerebral hemorrhage, have vascular dementia lasting more than three months, have shown minimal improvement despite medication, and have not seen any improvement in symptoms. This study, titled “The Effects of Autologous Blood-Derived Stem Cells on Patients with Vascular Dementia,” will examine the effects of selectively isolating cells from autologous blood and injecting them into the blood vessels that flow to the brain. The study will examine the effects of autologous blood-derived stem cells on improving dementia symptoms through neuroprotective effects and restoration of brain function. This clinical trial will utilize Miracell’s advanced stem cell extraction system, “Smart Mcell 2,” which has FDA registration and approval from the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, to extract highly safe stem cells. The BSC will be used to administer hematopoietic stem cells and various growth factors, including cytokines. Stem cells are progenitor cells that exist within the body. They are characterized by their outstanding regenerative ability, restoring damaged tissues to their original function. When stem cells are injected, the cells that migrate to the cerebral blood vessels are expected to regenerate cerebral vascular endothelial damage and strengthen existing blood vessels. The clinical trial uses autologous stem cells, so there are no side effects or costs. August 23, 2022

Miracell to Participate in Singapore Medical Fair 2022

Miracell to Participate in Singapore Medical Fair 2022 BoothIntroducing the “SMART M-CELL 2” Stem Cell Extraction System 【Health Digest | Reporter Choi Min-young】 Stem cell specialist Miracell (CEO Shin Hyun-soon) will showcase its stem cell extraction system, the “SMART M-CELL 2,” at the large-scale medical device exhibition “MEDICAL FAIR ASIA 2022,” held at Marina Bay Sands in Singapore from August 31st to September 2nd. The newly unveiled “SMART M-CELL 2” is an automated system capable of selectively isolating, extracting, and concentrating stem cells in just 17 minutes. Its key technology is its ability to maximize cell viability. This system automatically adjusts the RPM and angle of the separation vessel, reducing friction between vessels to minimize cell damage. Its closed system, which prevents air contact, is a bio-digital device equipped with LEDs that stimulate cell activity. Because it utilizes autologous bone marrow or blood, it is safe from immune rejection and side effects, and is used in hospitals and clinics nationwide, including university hospitals. According to the company, it has secured GMP, ISO 13485, ISO 9001, and European CE certifications, as well as 22 domestic and international patents for cell extraction technology, securing its source technology for stem cell technology. Following certification as a New Health Technology and Government Innovation Product, it recently completed FDA registration. CEO Shin Hyun-soon stated, “With the attention of many medical professionals and healthcare professionals at this year’s Singapore Medical Fair, Smart Mcell 2, a core system in regenerative medicine, is drawing closer to entering the global market.” Meanwhile, Miracell plans to participate in the ISAPS International Congress of Aesthetic Plastic Surgery, held in Istanbul, Turkey, from September 20th, and the IMCAS International Congress of Aesthetic Plastic Surgery, held in Bangkok, Thailand, from September 29th, to promote its advanced stem cell extraction system and expand exports.

Miracell Donates Goods to Beautiful Store

Miracell donates items to Beautiful Store [Reporter Lee Ji-yeon] Stem cell company Miracell (CEO Shin Hyun-soon) announced on the 30th that as part of its social contribution activities, its employees donated approximately 320 items, including clothing and lifestyle fashion items, to the Beautiful Store. Miracell stated, “With the idea that anyone can participate, we decided to donate items to the Beautiful Store as a volunteer initiative,to contribute a small amount to the underprivileged communities around us.” Miracell CEO Shin Hyun-soon stated, “This donation has provided an opportunity for all employees to realize the value of sharing through resource recycling.” She added, “We will continue this sustainable product sharing activity annually,and plan to gradually expand the scale of our social contribution activities beyond product donations.” Meanwhile, Miracell announced that it is expanding its bio stem cell extraction system, “Smart Mcell 2,”not only to domestic hospitals and clinics,but also to global markets such as Europe and the Middle East.